Methodology of antiemetic trials

Response assessment, evaluation of new agents and definition of chemotherapy emetogenicity

Paul J. Hesketh, Richard J. Gralla, Andreas Du Bois, Maurizio Tonato

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Establishing appropriate and practical methodology is a key to progress in the investigation of chemotherapy-induced nausea and vomiting. Critical issues include patient response assessment, proper trial design for evaluating new agents, and the definition of chemotherapy emetogenicity. In assessing antiemetic response, the primary end-point should be complete control of emesis and nausea. Emesis and nausea should be independently assessed with the period of observation defined (acute, delayed, anticipatory). Emesis can be evaluated by measuring the number of emetic episodes either by direct observation or by patient self-report using patient-completed diaries. Nausea should be measured by patient self-report with the standard parameters, including frequency and intensity. New antiemetic drug development should proceed in an orderly progression from open-label phase I-II trials defining tolerance and minimally fully effective dose to phase III comparative trials. A randomized, parallel, double-blind study is the preferred design for the latter, and the comparator arm should always include the current best available treatment. Antiemetic placebos are no longer acceptable with chemotherapy regimens known to produce emesis in a majority of patients. None of the emetogenic classifications proposed to date adequately accounts for all known important patient- and treatment-related prognostic variables. A modification of a recently reported schema is proposed for use in making antiemetic treatment recommendations and defining the emetogenic challenge in clinical trials.

Original languageEnglish (US)
Pages (from-to)221-227
Number of pages7
JournalSupportive Care in Cancer
Volume6
Issue number3
DOIs
StatePublished - May 1998
Externally publishedYes

Fingerprint

Antiemetics
Vomiting
Drug Therapy
Nausea
Self Report
Observation
Emetics
Double-Blind Method
Therapeutics
Placebos
Clinical Trials

Keywords

  • Antiemetic
  • Emesis
  • Emetogenicity
  • Methodology
  • Nausea

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Methodology of antiemetic trials : Response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. / Hesketh, Paul J.; Gralla, Richard J.; Du Bois, Andreas; Tonato, Maurizio.

In: Supportive Care in Cancer, Vol. 6, No. 3, 05.1998, p. 221-227.

Research output: Contribution to journalArticle

@article{3c5f312ee1fc45158f8fea8145cd8287,
title = "Methodology of antiemetic trials: Response assessment, evaluation of new agents and definition of chemotherapy emetogenicity",
abstract = "Establishing appropriate and practical methodology is a key to progress in the investigation of chemotherapy-induced nausea and vomiting. Critical issues include patient response assessment, proper trial design for evaluating new agents, and the definition of chemotherapy emetogenicity. In assessing antiemetic response, the primary end-point should be complete control of emesis and nausea. Emesis and nausea should be independently assessed with the period of observation defined (acute, delayed, anticipatory). Emesis can be evaluated by measuring the number of emetic episodes either by direct observation or by patient self-report using patient-completed diaries. Nausea should be measured by patient self-report with the standard parameters, including frequency and intensity. New antiemetic drug development should proceed in an orderly progression from open-label phase I-II trials defining tolerance and minimally fully effective dose to phase III comparative trials. A randomized, parallel, double-blind study is the preferred design for the latter, and the comparator arm should always include the current best available treatment. Antiemetic placebos are no longer acceptable with chemotherapy regimens known to produce emesis in a majority of patients. None of the emetogenic classifications proposed to date adequately accounts for all known important patient- and treatment-related prognostic variables. A modification of a recently reported schema is proposed for use in making antiemetic treatment recommendations and defining the emetogenic challenge in clinical trials.",
keywords = "Antiemetic, Emesis, Emetogenicity, Methodology, Nausea",
author = "Hesketh, {Paul J.} and Gralla, {Richard J.} and {Du Bois}, Andreas and Maurizio Tonato",
year = "1998",
month = "5",
doi = "10.1007/s005200050157",
language = "English (US)",
volume = "6",
pages = "221--227",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Methodology of antiemetic trials

T2 - Response assessment, evaluation of new agents and definition of chemotherapy emetogenicity

AU - Hesketh, Paul J.

AU - Gralla, Richard J.

AU - Du Bois, Andreas

AU - Tonato, Maurizio

PY - 1998/5

Y1 - 1998/5

N2 - Establishing appropriate and practical methodology is a key to progress in the investigation of chemotherapy-induced nausea and vomiting. Critical issues include patient response assessment, proper trial design for evaluating new agents, and the definition of chemotherapy emetogenicity. In assessing antiemetic response, the primary end-point should be complete control of emesis and nausea. Emesis and nausea should be independently assessed with the period of observation defined (acute, delayed, anticipatory). Emesis can be evaluated by measuring the number of emetic episodes either by direct observation or by patient self-report using patient-completed diaries. Nausea should be measured by patient self-report with the standard parameters, including frequency and intensity. New antiemetic drug development should proceed in an orderly progression from open-label phase I-II trials defining tolerance and minimally fully effective dose to phase III comparative trials. A randomized, parallel, double-blind study is the preferred design for the latter, and the comparator arm should always include the current best available treatment. Antiemetic placebos are no longer acceptable with chemotherapy regimens known to produce emesis in a majority of patients. None of the emetogenic classifications proposed to date adequately accounts for all known important patient- and treatment-related prognostic variables. A modification of a recently reported schema is proposed for use in making antiemetic treatment recommendations and defining the emetogenic challenge in clinical trials.

AB - Establishing appropriate and practical methodology is a key to progress in the investigation of chemotherapy-induced nausea and vomiting. Critical issues include patient response assessment, proper trial design for evaluating new agents, and the definition of chemotherapy emetogenicity. In assessing antiemetic response, the primary end-point should be complete control of emesis and nausea. Emesis and nausea should be independently assessed with the period of observation defined (acute, delayed, anticipatory). Emesis can be evaluated by measuring the number of emetic episodes either by direct observation or by patient self-report using patient-completed diaries. Nausea should be measured by patient self-report with the standard parameters, including frequency and intensity. New antiemetic drug development should proceed in an orderly progression from open-label phase I-II trials defining tolerance and minimally fully effective dose to phase III comparative trials. A randomized, parallel, double-blind study is the preferred design for the latter, and the comparator arm should always include the current best available treatment. Antiemetic placebos are no longer acceptable with chemotherapy regimens known to produce emesis in a majority of patients. None of the emetogenic classifications proposed to date adequately accounts for all known important patient- and treatment-related prognostic variables. A modification of a recently reported schema is proposed for use in making antiemetic treatment recommendations and defining the emetogenic challenge in clinical trials.

KW - Antiemetic

KW - Emesis

KW - Emetogenicity

KW - Methodology

KW - Nausea

UR - http://www.scopus.com/inward/record.url?scp=0031922859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031922859&partnerID=8YFLogxK

U2 - 10.1007/s005200050157

DO - 10.1007/s005200050157

M3 - Article

VL - 6

SP - 221

EP - 227

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 3

ER -